Ann: Efficacy for CYP MSC Technology in Preclinical Asthma Study-CYP.AX, page-28

Lumberjack, yes the story keeps building. This company's prospects are of the kind that inspire fear of missing out, castles in the air, call it what you will. They are doing their best to communicate to the market the latent potential of cymerus, but in the end the market is both largely ignorant and fearful of biotech. So it looks like they will have to show some revenue generating deals to convince investors. The good news is that biotech has been so bad an investment in the last couple of years, that it looks to have bottomed out, and I hope that the recent months interest will continue.